• eoh2014

  • Slideshow_knowmorehepc

  • Slideshow_hivhealthreform

  • slide_communityconnext

  • Slideshow_prep

Project Inform’s remarks for “Rally for PrEP SF!”

post_prepaccess

Below is the transcript of remarks that Project Inform provided on Thursday, September 18, 2014 at the “Rally for PrEP SF” event, City Hall, scheduled by Supervisor Campos. Project Inform heartily supports Supervisors Campos’s and Weiner’s goal of ensuring easy access to PrEP for all San…Read More

Rally for PrEP in San Francisco, Sept 18!

post_preprallysf

PrEP is the first pill approved by the FDA that stops the spread of HIV. But fewer than 1,000 people in San Francisco have access to the medication. Supervisor David Campos is holding a hearing to ask the City to make PrEP available to all San…Read More

Project Inform launches “I Deserve a Hep C Cure” social media campaign

post_hcv_campaign

Go to Hep C Cure release form. Project Inform and its community partners are initiating a campaign to counteract the rationing of hepatitis C treatment that is going on throughout the country. Many private and public payers (e.g., state Medicaid programs) are limiting access to hepatitis…Read More

CDC urged to determine why gay men are at greater risk of meningitis infection

post_la_lgbtcenter

From press release by Los Angeles LGBT Center: Contact: Gil Diaz, 323-993-7604, gdiaz@lalgbtcenter.org CDC Urged by Los Angeles LGBT Center, Leading AIDS Organizations to Determine Why Gay/Bisexual Men are at Greater Risk of Meningitis Infection LOS ANGELES, September 11, 2014—The Los Angeles LGBT Center’s medical director, Dr….Read More

Egrifta distribution resumes in the US to replenish supply chain

post_egrifta

Note from Project Inform: For patients who had their Egrifta prescription refills interrupted, it is likely you/your provider will need to fill out initial paperwork to re-start Egrifta, because this is a new company that’s responsible for its distribution. Other than that, there shouldn’t be any…Read More

NIH-led scientists discover HIV antibody that binds to novel target on virus

post_gp41gp120

WHAT: An NIH-led team of scientists has discovered a new vulnerability in the armor of HIV that a vaccine, other preventive regimen or treatment could exploit. The site straddles two proteins, gp41 and gp120, that jut out of the virus and augments other known places where…Read More

HIV medical organizations challenge insurer restrictions to HCV treatment

post_hcvmedicaid

WASHINGTON, DC – The American Academy of HIV Medicine (AAHIVM) and the HIV Medicine Association (HIVMA), the two largest professional associations representing HIV clinicians in the U.S., are challenging new health plan cost control policies barring many qualified HIV care providers from prescribing certain medications that treat…Read More